Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Day One Biopharmaceuticals (DAWN) Revenue (2024 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Revenue for 2 consecutive years, with $53.7 million as the latest value for Q4 2025.

  • For Q4 2025, Revenue rose 83.92% year-over-year to $53.7 million; the TTM value through Dec 2025 reached $158.2 million, up 20.6%, while the annual FY2025 figure was $158.2 million, 20.6% up from the prior year.
  • Revenue was $53.7 million for Q4 2025 at Day One Biopharmaceuticals, up from $39.8 million in the prior quarter.
  • The five-year high for Revenue was $93.8 million in Q3 2024, with the low at $8.2 million in Q2 2024.